Articles Tagged With: Pharmacology
-
The Effect of Antiviral Drugs on COVID-19 Outcomes and Mortality
The WHO Solidarity Trial Consortium found remdesivir, hydroxychloroquine, lopinavir, and interferon regimens produced “little or no effect” on relevant outcomes. -
Pegcetacoplan Injection (Empaveli)
The FDA has approved a new treatment for paroxysmal nocturnal hemoglobinuria, a rare, life-threatening blood disease. -
Time of the Essence with Dapagliflozin for Heart Failure
By adding dapagliflozin to maximally tolerated standard therapy for heart failure with reduced left ventricular ejection fraction, researchers noted the reduction in mortality and recurrent heart failure began within one month of starting this therapy. -
Dasiglucagon Injection (Zegalogue)
Dasiglucagon should be prescribed to treat severe hypoglycemia in pediatric and adult patients (≥ age 6 years).
-
Another Agent for Hypercholesterolemia
A pooled analysis of three randomized, controlled trials of inclisiran in patients with atherosclerotic cardiovascular disease or its risk equivalent showed impressive reductions in LDL cholesterol with subcutaneous injections every six months.
-
Bamlanivimab and Etesevimab Injection
Bamlanivimab and etesevimab should be prescribed to treat mild-to-moderate COVID-19 in adults and pediatric patients (age 12 years and older, weight at least 40 kg) who test positive for COVID-19 and are at high risk for progressing to severe disease and/or hospitalization.
-
Vericiguat Tablets (Verquvo)
Vericiguat is indicated to lower the risk of cardiovascular death and heart failure hospitalization in adults with symptomatic chronic heart failure and an ejection fraction less than 45%.
-
Relugolix Tablets (Orgovyx)
Relugolix should be prescribed to adults with advanced prostate cancer.
-
Tirbanibulin Ointment (Klisyri)
Tirbanibulin is indicated for the topical treatment of actinic keratosis on the face and scalp.
-
Using Sacubitril/Valsartan to Treat Heart Failure with Preserved Ejection Fraction
An analysis of renal outcomes in the PARAGON-HF trial revealed sacubitril/valsartan slows progression of kidney disease in patients with heart failure with preserved ejection fraction compared to valsartan alone.